Amsterdam-based medical research platform EvidenceHunt has raised €1.2 million in funding from Keen Venture Partners, Dff.ventures, and Slimmer AI. The funds will be used to enhance its AI platform, improve enterprise integration, and support global expansion.
- EvidenceHunt, founded in 2023 by Philippe Habets and Olivier Magnin, develops an AI-powered medical research platform designed to streamline the process of finding, analyzing, and utilizing medical evidence.
- The platform enables users to ask questions and get summarized, evidence-based answers in seconds, with cited sources and verifiable details. It also includes advanced features like powerful filters, collaboration tools, and custom data integration.
- The platform leverages AI to eliminate manual searching through databases like PubMed, guidelines, and protocols, saving professionals such as healthcare providers, medical scientists, and researchers up to 5 hours per week.
"Unlike generic AI platforms, our goal with EvidenceHunt is not to be a black box; it’s designed to empower users with transparency and reliability, which are essential for adoption and for earning the trust of the medical community,” claims Philippe Habets, CEO of EvidenceHunt.
- To date, EvidenceHunt has grown to 25,000 active users across 90+ countries. The platform claims to answer questions 10 times faster than traditional methods, with over 150,000 questions answered monthly.
- The firm is trusted by over 250 institutions, including Pfizer, Google, UCL, University of Cambridge, and Columbia University, it empowers professionals worldwide.
Details of the deal
- The investment was led by Keen Venture Partners, an Amsterdam-based venture capital firm supporting startups across Europe, along with Amsterdam-based VC Dff.ventures and Dutch AI venture studio Slimmer AI.
“EvidenceHunt addresses a clear pain point for users across various segments worldwide. By integrating into institutional workflows and with institutional data, and applying the latest LLM technology in a powerful vertical-AI SaaS solution, EvidenceHunt taps into a large and growing market," Investor JC Heyneke from Slimmer AI, and former GM at Elsevier, stated.
- The round also saw participation from notable business angels, including Jeroen Tas, Dinko Valerio, and James Shannon.
- The fresh capital raised will enable EvidenceHunt to enhance its AI platform, integrate into institutional workflows, expand globally, and develop advanced collaboration features.
